A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

HIV Infections Clinical Trial

— VOGUE  

Official title:

A Phase 3b, Multi-center, Randomized, Parallel-group, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen Compared to Oral Bictegravir/Emtricitabine/Tenofovir Alafenamide Once Daily for Virologic Suppression and Maintenance in Antiretroviral Therapy Naive Adults Living With HIV

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05979311
• Other study ID #: 219816
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: December 29, 2023
• Est. completion date: August 24, 2026

Study information

• Verified date: December 2023
• Source: ViiV Healthcare
• Contact: US GSK Clinical Trials Call Center
• Phone: 877-379-3718
• Email: GSKClinicalSupportHD[@]gsk.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will compare safety, efficacy, participant reported outcomes and implementation outcomes of a fixed dose combination (FDC) of a two-drug regimen dolutegravir (DTG) plus lamivudine (3TC) and a three-drug regimen FDC of bictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF) in HIV-1 infected adult participants who have not previously received antiretroviral therapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 412
• Est. completion date: August 24, 2026
• Est. primary completion date: September 22, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants with age >=18 years (or older, if required by local regulations) at the time of obtaining informed consent.
• An individual participant is eligible to participate if they are not pregnant (as confirmed by a negative serum human chorionic gonadotropin (hCG) test at Screening and a negative urine hCG test at Enrollment) and not lactating.
• Antiretroviral-naïve (no prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) person living with HIV.
• Participant (or participant's legally acceptable representative [LAR]) is capable of giving written informed consent.
• Eligible participants or their LAR must sign a written Informed Consent Form before any protocol-specified assessments are conducted. Enrollment of participants who are unable to provide direct informed consent is optional and will be based on local legal/regulatory requirements and site feasibility to conduct protocol procedures.
• Participants enrolled in France must be affiliated to, or a beneficiary of, a social security category.

Exclusion Criteria:

• Individuals who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study.
• Any evidence of a current Centers for Disease Control and Prevention (CDC) Stage 3 disease; with the exception of cutaneous Kaposi's sarcoma not requiring systemic therapy, and CD4+ count <200 cells per cubic millimeter (neither is exclusionary).
• History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates study participation.
• Ongoing or clinically relevant pancreatitis.
• Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the Investigator and the Medical Monitor for inclusion of the participant prior to enrollment.
• Participants with severe hepatic impairment (Class C) as determined by Child-Pugh classification.
• Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
• History of liver cirrhosis with or without hepatitis viral co-infection.
• Alanine aminotransferase (ALT) >=5 times the upper limit of normal (ULN) or ALT >=3*ULN and bilirubin >=1.5*ULN (with >35% direct bilirubin).
• Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrollment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrollment.
• Participants who, in the investigator's judgment, pose a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
• Signs and symptoms which, in the opinion of the Investigator, are suggestive of active Coronavirus disease 2019 (COVID-19) (example fever, cough) infection within 14 days prior to enrollment.
• Evidence of Hepatitis B virus (HBV) infection based on the results of central lab testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis B surface antibody (HBsAb) and HBV Deoxyribonucleic Acid (DNA) as follows: a. Participants positive for HBsAg are excluded; b. Participants negative for HBsAb and negative for HBsAg but positive for hepatitis B core antibody (HBcAb) may be excluded based on the following consideration: i. Exclude if HBV DNA is detected [either <Lower Limit of Quantification (LLoQ), >Upper Limit of Quantification (ULoQ) OR numerical value (i.e., between LLoQ and ULoQ)] ii. Not excluded if HBV DNA is negative, not detected
• Participants with Hepatitis C virus (HCV) co-infection at Screening are eligible only if: i. liver enzymes meet entry criteria; and ii. HCV disease is not anticipated to require on-study treatment with any agent(s) that have potential adverse drug-drug interactions (DDIs) with the study interventions; and iii. HCV disease has undergone appropriate work-up and is not advanced and will not require treatment prior to the primary endpoint or later visit. Additional information on participants with HCV co-infection at screening should include results from any liver biopsy, Fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment. iv. In the event that recent biopsy or imaging data is not available or inconclusive, the Fib-4 score will be used to verify eligibility

1. Fib-4 score >3.25 is exclusionary;

2. Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation. Fibrosis 4 score Formula: (Age * Aspartate aminotransferase [AST]) / (Platelets * (square root of ALT)

• Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded. Participants with a false positive RPR (with negative treponemal test) or serofast RPR result (persistence of a reactive nontreponemal syphilis test despite history of adequate therapy and no evidence of re-exposure) may enroll after consultation with the Medical Monitor. Participants who completed treatment at least 7 days prior to Screening are eligible.
• Presence of any major resistance-associated mutations as defined by the International Antiviral Society-United States of America (IAS-USA) resistance guidelines to DTG, 3TC, BIC, FTC or TAF in the Screening result.
• Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to first dose of study treatment.
• Treatment with any of the following agents within 28 days of Screening:

i. radiation therapy; ii. cytotoxic chemotherapeutic agents; iii. tuberculosis therapy with the exception of isoniazid (isonicotinylhydrazid, INH); iv. immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.

• Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
• Treatment with any agent with documented activity against HIV-1 in vitro within 28 days of first dose of study treatment. Treatment withacyclovir/valacyclovir is permitted.
• Participants receiving any protocol-defined prohibited medication and who are unwilling or unable to switch to an alternate medication.
• Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 lipid abnormalities.
• Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in an interventional clinical trial.
• Participant has estimated creatine clearance <30 milliliter per minute (mL/min) per 1.73 square meter using the refitted, race-neutral Chronic Kidney Disease Epidemiology Collaboration (CKD-EPIcr_R) method.
• Participants known or suspected to have acquired HIV-1 concurrent with use of Pre-exposure prophylaxis (PrEP) or Post-exposure prophylaxis (PEP) must be discussed with the Medical Monitor prior to enrollment.
• Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study medication.
• Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
• Participant is currently participating in, or anticipates being selected for, any other interventional study.

Related Conditions & MeSH terms

• HIV
• HIV Infections

Intervention

Drug:
• Dolutegravir
Dolutegravir will be administered once daily.
• Lamivudine
Lamivudine will be administered once daily.
• Bictegravir
Bictegravir will be administered once daily.
• Emtricitabine
Emtricitabine will be administered once daily.
• Tenofovir alafenamide
Tenofovir alafenamide will be administered once daily.

Locations

Country	Name	City	State
Argentina	GSK Investigational Site	Ciudad Autonoma de Buenos Aires	Buenos Aires
Argentina	GSK Investigational Site	Cordoba	Córdova
Belgium	GSK Investigational Site	Antwerpen
Belgium	GSK Investigational Site	Brussels
Belgium	GSK Investigational Site	Gent
Denmark	GSK Investigational Site	Hvidovre
France	GSK Investigational Site	Bordeaux
France	GSK Investigational Site	Bordeaux
France	GSK Investigational Site	Montpellier
France	GSK Investigational Site	Nice Cedex 3
France	GSK Investigational Site	Nîmes
France	GSK Investigational Site	Paris
France	GSK Investigational Site	Paris
France	GSK Investigational Site	Paris
France	GSK Investigational Site	Paris cedex 20
France	GSK Investigational Site	Toulouse cedex 9
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Frankfurt	Hessen
Germany	GSK Investigational Site	Hamburg
Germany	GSK Investigational Site	Koeln	Nordrhein-Westfalen
Germany	GSK Investigational Site	München
Greece	GSK Investigational Site	Athens
Greece	GSK Investigational Site	Athens
Greece	GSK Investigational Site	Thessaloniki
Ireland	GSK Investigational Site	Dublin
Ireland	GSK Investigational Site	Dublin
Israel	GSK Investigational Site	Haifa
Israel	GSK Investigational Site	Ramat Gan
Israel	GSK Investigational Site	Rehovot
Israel	GSK Investigational Site	Tel Aviv
Italy	GSK Investigational Site	Bari	Puglia
Italy	GSK Investigational Site	Bergamo	Lombardia
Italy	GSK Investigational Site	Padova
Italy	GSK Investigational Site	Pavia
Italy	GSK Investigational Site	Sassari	Sardegna
Japan	GSK Investigational Site	Aichi
Japan	GSK Investigational Site	Osaka
Japan	GSK Investigational Site	Tokyo
Japan	GSK Investigational Site	Tokyo
Mexico	GSK Investigational Site	García Gineres	Mérida
Mexico	GSK Investigational Site	Zapopan	Jalisco
Poland	GSK Investigational Site	Bydgoszcz
Poland	GSK Investigational Site	Lodz
Poland	GSK Investigational Site	Wroclaw
Portugal	GSK Investigational Site	Aveiro
Portugal	GSK Investigational Site	Porto
Spain	GSK Investigational Site	Badalona
Spain	GSK Investigational Site	Barcelona
Spain	GSK Investigational Site	Elche
Spain	GSK Investigational Site	las Palmas de Gran Canaria	Canary Islands
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Marbella
Spain	GSK Investigational Site	Palma de Mallorca
Spain	GSK Investigational Site	Palma de Mallorca
Spain	GSK Investigational Site	Valencia
Sweden	GSK Investigational Site	Stockholm
Switzerland	GSK Investigational Site	Basel
Switzerland	GSK Investigational Site	Zürich
United Kingdom	GSK Investigational Site	Glasgow
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	London

Sponsors (1)

Lead Sponsor	Collaborator
ViiV Healthcare

Countries where clinical trial is conducted

Argentina,  Belgium,  Denmark,  France,  Germany,  Greece,  Ireland,  Israel,  Italy,  Japan,  Mexico,  Poland,  Portugal,  Spain,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants with plasma HIV- Ribonucleic acid (RNA) less than (<)50 copies per milliliter (c/mL) as per snapshot algorithm at Week 48		Week 48
Secondary	Percentage of participants with plasma HIV-1 RNA <50 c/mL as per snapshot algorithm at Weeks 24 and 96		Weeks 24 and 96
Secondary	Percentage of participants with HIV-RNA greater than or equal to (>=)50 c/mL as per snapshot algorithm at Weeks 24, 48, and 96		Weeks 24, 48 and 96
Secondary	Change from Baseline in HIV-1 RNA at Weeks 24, 48 and 96		Baseline (Day 1) and Weeks 24, 48 and 96
Secondary	Change from Baseline in Cluster of differentiation 4 positive (CD4+) cell count at Weeks 24, 48 and 96		Baseline (Day 1) and Weeks 24, 48 and 96
Secondary	Change from Baseline in CD4/Cluster of differentiation 8 (CD8) at Weeks 24, 48 and 96		Baseline (Day 1) and Weeks 24, 48 and 96
Secondary	Number of Participants With HIV-1 Disease Progression		Weeks 24, 48 and 96
Secondary	Time to virologic suppression (HIV-1 RNA <50 c/mL) from Baseline		Baseline (Day 1) and Up to Week 96
Secondary	Number of participants with confirmed virologic withdrawal (CVW)		Up to Week 96
Secondary	Number of Participants with treatment-emergent resistance		Up to week 96
Secondary	Change from Baseline in Renal Biomarkers- estimated glomerular filtration rate at Weeks 48 and 96		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in Renal Biomarkers- urinary protein/creatinine at Weeks 48 and 96		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in renal biomarker- Serum Cystatin C at Weeks 48 and 96 (Milligrams per liter)		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in renal biomarker- Serum Retinol Binding Protein (RBP) at Weeks 48 and 96 (Milligrams per deciliter)		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in renal biomarker- Serum Beta-2 Microglobulin (B2M) at Weeks 48 and 96 (Micrograms per milliliter)		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in bone biomarkers- Serum Bone Specific Alkaline Phosphatase, Serum Procollagen type 1 N- Propeptide, Serum Type I Collagen C-Telopeptides and Serum Osteocalcin at Weeks 48 and 96 (Micrograms per Liter)		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in bone biomarkers- Serum Vitamin D at Weeks 48 and 96 (Nanomoles per Liter)		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline (Week 4) in Total Treatment Satisfaction Score Using HIV Treatment Satisfaction status Questionnaire (HIVTSQs) at Weeks 12, 24, 48 and 96 (Scores on a scale)	The HIVTSQ status version (HIVTSQs) is assessing participants' satisfaction with their current treatment with a Total score ranging from 0 to 60. Higher scores indicate a greater level of satisfaction with HIV treatment. Baseline is defined as measurement value at Week 4.	Baseline (Week 4) and Weeks 12, 24, 48 and 96
Secondary	Change from Baseline (Week 4) in Individual Item Scores Using HIVTSQs at Weeks12, 24, 48 and 96 (Scores on a scale)	Individual items scores range from 0 to 6 (0=very dissatisfied, 6=very satisfied). Baseline is defined as measurement value at Week 4.	Baseline (Week 4) and Weeks 12, 24, 48 and 96
Secondary	Change from Baseline (Week 4) in Domains Scores Using HIVTSQs at Weeks 12, 24, 48 and 96 (Scores on a scale)	There are two domain scores of General Satisfaction/Clinical and Lifestyle/Ease subscales; each comprised of 5 items with possible scores of 0 to 30. The higher the score, the greater the satisfaction within the subscale. Baseline is defined as measurement value at Week 4.	Baseline (Week 4) and Weeks 12, 24, 48 and 96
Secondary	Change from Baseline in bothersome symptoms using the Symptom Distress Module at Weeks 4, 12, 24, 48 and 96 (Score on a scale)	The Symptom Distress Module (SDM) is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom bother score is based on the score for each symptom present ranging from 1 (it does not bother me) to 4 (it bothers me a lot). Symptom bother score is the unweighted sum of the bother item scores for each symptom. The symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score).	Baseline (Day 1) and Weeks 4, 12, 24, 48 and 96
Secondary	Absolute values for waist and hip circumference (Centimeters)		Up to Week 96
Secondary	Absolute values for waist to hip ratio and waist to height ratio (Ratio)		Up to Week 96
Secondary	Absolute values for Body weight (Kilogram)		Up to Week 96
Secondary	Absolute values for systolic and diastolic blood pressure (millimeters of mercury)		Up to Week 96
Secondary	Change from Baseline in Body Mass Index (kilogram per square meter)		Baseline (Day 1) and Up to Week 96
Secondary	Change from Baseline in body weight greater than (>) 5 percentage (%) at Weeks 24, 48 and 96		Baseline (Day 1) and Weeks 24, 48 and 96
Secondary	Change from Baseline in total and regional (trunk and extremities) fat assessed by Dual-energy X-ray absorptiometry (DXA) at Weeks 48 and 96		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in total and regional (trunk and extremities) fat-free mass assessed by DXA Weeks 48 and 96		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in lumbar and hip bone mineral density (BMD) assessed by DXA at Weeks 48 and 96		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in trabecular bone score (TBS) assessed by DXA at Weeks 48 and 96	Trabecular bone score (TBS) is a lumbar spine dual-energy absorptiometry texture index, which provides information on microarchitecture skeletal quality partially independent of BMD.	Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in fasting glucose (Millimoles per Liter)		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in insulin (Microunits per millilliter)		Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Week 48 and Week 96		Baseline (Day 1), Week 48 and Week 96
Secondary	Change from Baseline in Hemoglobin A1c [HbA1c] at Week 48 and Week 96 (Percentage of HbA1c)		Baseline (Day 1), Week 48 and Week 96
Secondary	Change from Baseline in plasma lipids (total, high-density lipoprotein [HDL], and low-density lipoprotein [LDL] cholesterol, triglycerides) (Millimoles per Liter) at Week 48 and Week 96		Baseline (Day 1), Week 48 and Week 96
Secondary	Change from Baseline in QDiabetes Score at Week 48 and Week 96 (Scores on a scale)	QDiabetes score defines the risk (percentage) of developing type 2 Diabetes in the next ten years. The score ranges from 0-100.	Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in Fibrosis 4 (FIB-4) Score at Week 48 and Week 96 (Scores on a scale)	A value of FIB-4 scores below 1.30 is considered as low risk for advanced fibrosis; value of FIB-4 over 2.67 is considered as high risk for advanced fibrosis; and FIB-4 values between 1.30 and 2.67 are considered as intermediate risk of advanced fibrosis.	Baseline (Day 1), Weeks 48 and 96
Secondary	Number of participants with metabolic syndrome at Weeks 48 and 96		Weeks 48 and 96
Secondary	Change from Baseline in Framingham cardiovascular risk scores at Weeks 48 and 96 (Scores on a scale)	Coronary heart disease (CHD) risk at 10 years in percent (%) can be calculated with the help of the Framingham Risk Score. Individuals with low risk have 10% or less CHD risk at 10 years, with intermediate risk 10-20%, and with high risk 20% or more.	Baseline (Day 1), Weeks 48 and 96
Secondary	Change from Baseline in Data collection on Adverse events of anti-HIV Drugs (DAD) cardiovascular risk scores at Weeks 48 and 96 (Scores on a scale)	Coronary heart disease (CHD) risk at 5 years in percent can be calculated with the help of the DAD Risk Score. The 5-year risk of CHD is classified as low (<1%), moderate (1 to 5%), high (5 to 10%), or very high (>10%).	Baseline (Day 1), Weeks 48 and 96
Secondary	Changes from Baseline in Systolic and diastolic blood pressure at Weeks 48 and 96 millimeters of mercury (mmHg)		Baseline (Day 1), Weeks 48 and 96